Helicid Rapid (Omeprazole)

Helicid Rapid is indicated for several acid‑related gastrointestinal conditions where reduction of gastric acidity is desired.

• Gastroesophageal reflux disease (GERD), to relieve heartburn and acid regurgitation.
• Peptic ulcer disease, including duodenal and gastric ulcers, to promote healing.
• Erosive esophagitis, to allow mucosal recovery and prevent further damage.
• Prevention of ulcer formation in patients taking non‑steroidal anti‑inflammatory drugs (NSAIDs).
• Maintenance therapy after healing of erosive esophagitis to reduce recurrence.
• Adjunctive therapy for Zollinger‑Ellison syndrome when combined with other agents.
• Use in Helicobacter pylori eradication regimens as part of triple therapy.

The safety profile of Helicid Rapid reflects the typical experience with omeprazole, with most patients reporting mild, transient effects.

Common

• Headache.
• Abdominal pain or discomfort.
• Diarrhea.
• Nausea.
• Flatulence.
• Constipation.

Serious

• Severe allergic reactions such as anaphylaxis or angioedema.
• Clostridioides difficile associated diarrhea.
• Low serum magnesium levels (hypomagnesemia).
• Elevated liver enzymes indicating possible hepatic injury.

When prescribing or using Helicid Rapid, clinicians and patients should consider several precautionary measures to ensure safe and effective therapy.

• Do not use in individuals with known hypersensitivity to omeprazole or other proton pump inhibitors.
• Use with caution in patients with severe hepatic impairment.
• Long‑term therapy may increase the risk of vitamin B12 deficiency; monitoring is advised.
• The medication can mask symptoms of gastric malignancy; appropriate diagnostic evaluation is recommended if symptoms persist.
• Dose adjustment may be required in patients with renal impairment.
• Avoid abrupt discontinuation after prolonged use to prevent rebound acid hypersecretion.
• Safety in pregnancy and lactation has not been fully established; consult a healthcare professional.

Helicid Rapid can affect the pharmacokinetics of other medicines; certain combinations should be avoided while others require monitoring.

Avoid

• Antifungal agents that require an acidic environment for absorption (e.g., ketoconazole, itraconazole).
• Antiretroviral drugs such as atazanavir that need low gastric pH.
• Clopidogrel, because omeprazole may reduce its antiplatelet activation.

Use with caution

• Warfarin, as omeprazole may enhance anticoagulant effects.
• Methotrexate, due to potential reduction in renal clearance.
• Digoxin, because plasma concentrations may increase.
• Diazepam and other benzodiazepines, which may have elevated levels when co‑administered.